Basel, Switzerland – 18 November 2021 – Arxada AG, a global specialty chemicals business, today announces that it will invest CHF 20m in its industrial biotechnological plant in Kouřim, Czech Republic, which serves the contract development and manufacturing organization (CDMO) part of its Specialty Products Solutions business. This investment provides important infrastructure debottlenecking in connection with expanded technological options and the addition of significant formulation capacity necessitated by Arxada’s growing customer base.
Antje Gerber, President, Specialty Products Solutions, Arxada, said:
“With this investment, we are strengthening our capacity to support our expanding customer base with their highly interesting and often technologically challenging projects.”
Lukas von Hippel, VP, CDMO Business Line, Arxada, commented:
“Our site in Kouřim is an integral part of our future strategy. Following the implementation of our new strategy in May 2020, we have seen more customers seeking our support in their new projects. Our business development team together with our process development team in Kouřim can speed up development and shorten time to market by over a year in some cases.”
Zdena Cermakova, Kouřim Site Head, Arxada, added:
“We are seeing growing demand for CDMO projects in biotech. Last week, one of the auditors auditing our site on behalf of a customer stated that he had never seen such a well-maintained site. This compliment raises the bar even higher, if possible.”
-- ENDS --
Global Head of Communications
Tel: +41 61 316 2054
Stephanie Cuthbert/Rob Winder
Tel: +44 20 3737 1000
Arxada, formerly part of Lonza Group, is a global specialty chemicals business with a world-class offering in Microbial Control Solutions (‘MCS’) and Specialty Products Solutions (‘SPS’). Arxada provides a broad portfolio of differentiated products targeted at a range of end uses, supported by its leading regulatory capabilities, IP expertise and established track record in R&D.
Arxada’s MCS business is a world leader addressing six target end uses: hygiene, home and personal care, paints and coatings, crop protection, material protection and wood protection. MCS is built on superior regulatory expertise, the broadest set of bioactives and the widest range of registrations in the world, which are critical to maintaining the integrity of its customers’ products.
Arxada’s SPS business provides complex, high-quality technologies and chemistries to customers across a range of industries within its three divisions: performance intermediates and chemicals, composite materials and the custom development and manufacturing organisation. The two businesses work closely together to provide complementary expertise and deliver unique, innovative solutions to help customers protect their products from harmful microorganisms, improve health and safety and reduce their environmental footprints.
Arxada has a global footprint spanning 32 countries across five continents. Its world-leading team of around 2,900 employees serve over 5,000 customers across a wide range of industries.
Arxada is owned by Bain Capital Private Equity and Cinven.